NCT00779194View on ClinicalTrials.gov

Prospective Study of Rapamycin for the Treatment of SLE

PHASE2CompletedINTERVENTIONAL

Enrollment

99

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

December 31, 2015

Study Completion Date

December 16, 2015

Conditions

Systemic Lupus Erythematosus (SLE)

Interventions

DRUG

Rapamycin

Rapamycin, is given to this group at a starting dose of 2 mg/day.

Trial Locations (1)

13210

SUNY Upstate Medical University, Syracuse

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Pfizer

INDUSTRY

lead

State University of New York - Upstate Medical University

OTHER